Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
6 Results for "
sequestosome
" in MedChemExpress (MCE) Product Catalog:
Products (6)
6 Results for "sequestosome" in MCE Product Catalog:
7
7 Publications Verification
XRK3F2 is a p62 (sequestosome-1) ZZ domain inhibitor that has specificity for the p62-ZZ domain over other p62 signaling domains. XRK3F2 blocks TNFα effects and upregulation in bone marrow stromal cells, and induces multiple myeloma cell apoptosis. XRK3F2 can be used for the research of multiple myeloma bone disease, acute myeloid leukemia, and multiple myeloma .
1
1 Cited Publications
Cat. No.: HY-P80518
Synonyms: ORCA, OSIL, SQSTM1, sequestosome-1, EBI3-associated protein of 60 kDa, Phosphotyrosine-independent ligand for the Lck SH2 domain of 62 kDa, Ubiquitin-binding protein p62, EBIAP, p60, p62
Cat. No.: HY-161746
CAS No.: 2941386-44-1
Research Areas:
Anle138b-F105 is an autophagy-targeting chimera (AUTOTAC) that targets p62/Sequestosome-1/SQSTM1. Anle138b-F105 binds to the ZZ domain of p62, induces conformational activation, self-oligomerization, interaction with LC3, and formation of autophagosomes. Anle138b-F105 induces autophagic flux of ubiquitin-conjugated aggregated proteins, leading to their lysosomal degradation. Anle138b-F105 is applicable for the research of neurodegenerative proteinopathies .
Cat. No.: HY-161739
CAS No.: 2409960-03-6
YOK-1304 is a p62/Sequestosome-1/SQSTM1 ligand that binds to the p62-ZZ domain. YOK-1304 promotes p62 self-oligomerization and LC3 interaction to facilitate autophagic targeting and p62-dependent selective autophagy. YOK-1304 enhances autophagic flux, induces LC3 puncta formation and p62-LC3 colocalization, and serves as an autophagy-targeting ligand (ATL) that can be linked to target-binding ligands to generate AUTOTAC degraders. YOK-1304 is used in research on cervical cancer and pancreatic cancer .
Cat. No.: HY-112904A
CAS No.: 2375193-42-1
XRK3F2 free base is a p62 (sequestosome-1) ZZ domain inhibitor that has specificity for the p62-ZZ domain over other p62 signaling domains. XRK3F2 free base blocks TNFα effects and upregulation in bone marrow stromal cells, and induces multiple myeloma cell apoptosis. XRK3F2 free base can be used for the research of multiple myeloma bone disease, acute myeloid leukemia, and multiple myeloma .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
